About this trial
The goal of this observational study is undertake a detailed phenotypic and genotypic study of patients with ocular and secondary cancers due to mutations in the RB1 gene. Our research sequencing approach will allow advanced insight to for further detailed genotypic understanding of parent-of-origin for valuable insight into the genotype-phenotype relationship of this cancer syndrome.
Eligibility criteria
Qualifiers
Patients with molecularly proven retinoblastoma due to RB1 or a typical clinical retinoblastoma phenotype with genetic screening pending.
Able to give consent/parent or guardian able to give consent.
Disqualifiers
Patients unable or unwilling to undertake consent or clinical testing.
Patients unwilling to donate a saliva or blood sample in order to establish the genetic cause of their condition.
Trial design
Treatments tested in this trial
- Targeted Long-read sequencing
Treatment groups
Sponsors and collaborators
University of Washington
Lead sponsor
National Eye Institute (NEI)
Collaborator